Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708015 | 0.82 | AAK1 (0.32) | — | |
| SCHEMBL7708185 | 0.81 | PARP1 (0.40) | NPSR1MEN1KMT2AATMSSTR4 | |
| SCHEMBL7711556 | 0.81 | NPC1 (0.33) | KMT2ANPC1RAB9A | |
| SCHEMBL7711071 | 0.80 | NAMPT (0.36) | RAB9A | |
| SCHEMBL7708340 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL7705086 | 0.76 | NPSR1 (0.35) | NPSR1MEN1KMT2AATMSSTR4 | |
| SCHEMBL6310050 | 0.69 | CA1 (0.34) | MEN1KMT2AGAA | |
| SCHEMBL7704833 | 0.68 | KDM4E (0.37) | NPSR1CTSSCTSK | |
| SCHEMBL4262988 | 0.66 | MEN1 (0.43) | MEN1KMT2AATMSSTR4NPC1 | |
| SCHEMBL7711362 | 0.66 | PTPRB (0.40) | NPSR1MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |